Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Nephrology

Standard Treatment and Kidney Protection

At a Glance

Immunotactoid glomerulopathy is treated by addressing the immune cells or underlying condition making damaging proteins, while medicines control blood pressure and urine protein. Early, sustained treatment may improve kidney function, but established scarring can limit recovery.

The primary goal of treating Immunotactoid Glomerulopathy (ITG) is to stop the underlying mechanism that is producing the abnormal proteins damaging your kidneys. Because ITG is so rare, there is no single established regimen or “FDA-approved” drug specifically for it. Evidence relies heavily on small observational series. Instead, doctors use a strategy called clone-directed therapy, where treatment is tailored to the specific type of immune cell (the clone) found in your blood or bone marrow [1][2].

Successfully treating ITG requires a close partnership between your nephrologist (kidney doctor) and your hematologist/oncologist (blood/cancer specialist) [3].

Treating Monoclonal ITG

In most cases of ITG, a single group of cells is producing the abnormal protein. Treatment focuses on eliminating these cells to achieve a hematologic response (reducing the protein in your blood), which is the strongest predictor of a renal response (improving kidney function) [1][4].

  • B-Cell Targeted Therapy: If your ITG is linked to B-cells (often seen in CLL or lymphoma), doctors sometimes use Rituximab, an off-label monoclonal antibody that “tags” B-cells for destruction [1][4]. In some cases, more intensive chemotherapy regimens like R-CHOP or targeted drugs like Ibrutinib are used as individualized examples [5][6].
  • Plasma Cell Targeted Therapy: If the proteins come from plasma cells (often seen in MGRS or Multiple Myeloma), treatments may involve Bortezomib or Daratumumab [7][8]. These drugs are designed to kill the specific cells that produce antibodies.
  • Outcomes: In a small study of 27 ITG patients, 18 out of 21 who received clone-directed treatment saw an improvement in their kidney function [4]. However, if the kidney damage is already very advanced (scars have formed), the kidneys may not fully recover even if the blood disorder is cured [9][4].

Treating Polyclonal ITG

If your ITG is polyclonal, it means multiple types of cells are involved, often due to an underlying infection or autoimmune disease. Treatment is highly individualized:

  • Infection Management: If a chronic infection like HIV or Hepatitis C is present, the priority is often treating the virus first. For example, some patients have seen kidney improvement simply by starting effective antiretroviral therapy for HIV [10][11].
  • Autoimmune Support: If an autoimmune condition (like rheumatoid arthritis) is the cause, doctors may use standard immunosuppressants like steroids or mycophenolate, though results for these in ITG specifically have been mixed and they are not established as standard care [12][13].

Supportive Nephroprotective Care

Regardless of the cause of your ITG, you will likely receive “supportive” treatments to protect your kidneys from further stress. These don’t treat the underlying disease, but they make the kidney’s job easier.

  1. Proteinuria Reduction: Drugs called ACE inhibitors (like lisinopril) or ARBs (like losartan) are common for lowering blood pressure inside the kidney filters and reducing the amount of protein that leaks into your urine [10][6]. These are alternatives, not to be combined, and require strict potassium and creatinine monitoring.
  2. SGLT2 Inhibitors: These medications have shown broad promise in protecting kidney function in chronic kidney disease by reducing pressure and inflammation in the kidney, though specific evidence in ITG is limited. They require caution regarding volume depletion [10].
  3. Blood Pressure Control: Keeping your blood pressure consistently controlled (often below 130/80 mmHg, but individualized) is essential to prevent additional scarring [14].

What to Expect Long-Term

Because the abnormal cells can sometimes return, long-term monitoring is vital. If you eventually require a kidney transplant, it is important to know that ITG can recur in the new kidney, especially if the underlying blood condition was not fully controlled before the transplant [15][1]. Early diagnosis and achieving a deep hematologic response remain your best tools for protecting your kidney health over the long term [4].

Common questions in this guide

What treatment is usually used for immunotactoid glomerulopathy?
There is no single established or FDA-approved treatment specifically for ITG. Doctors often use clone-directed therapy to treat the immune-cell group making the damaging protein, together with kidney-protective care and close nephrology and hematology or oncology follow-up.
How do doctors choose between B-cell and plasma-cell treatment for ITG?
Blood, bone marrow, and biopsy findings help identify whether a B-cell or plasma-cell group is producing the abnormal protein. B-cell-directed options can include rituximab, while plasma-cell-directed options can include bortezomib or daratumumab; treatment is individualized.
Can treatment improve kidney function in ITG?
Yes, kidney function can improve when treatment reduces the abnormal proteins, especially before severe scarring develops. In a small study, 18 of 21 patients receiving clone-directed treatment had kidney improvement, but advanced damage may not fully recover.
How is polyclonal immunotactoid glomerulopathy treated?
Treatment focuses on the underlying cause. Chronic infections such as HIV or hepatitis C may be treated first, while autoimmune disease may be managed with medicines such as steroids or mycophenolate; results for immunosuppressants in ITG have been mixed.
Which medicines help protect the kidneys in ITG?
ACE inhibitors or ARBs can lower pressure in the kidney filters and reduce urine protein, but they are alternatives and should not be combined. SGLT2 inhibitors may also support kidney protection, while blood pressure, potassium, kidney blood tests, and the risk of dehydration need monitoring.
How will doctors know whether ITG treatment is working?
Doctors monitor the abnormal protein in your blood for a hematologic response and track eGFR and urine protein for a kidney response. Your care team may also review swelling, foamy urine, blood pressure, medication tolerance, and side effects.
Can ITG come back after a kidney transplant?
Yes, ITG can recur in a transplanted kidney, especially if the underlying blood-cell disorder was not fully controlled before transplant. Achieving a deep response and continuing long-term follow-up can help protect the new kidney.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Immunotactoid glomerulopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my biopsy and hematology workup, are we targeting a B-cell clone or a plasma cell clone?
  2. 2.Which specific chemotherapy or immunotherapy regimen do you recommend for my situation?
  3. 3.What is the 'hematologic response' goal we are aiming for to give my kidneys the best chance at recovery?
  4. 4.Are my current blood pressure and proteinuria levels low enough, or should we consider an ACE inhibitor, ARB, or SGLT2 inhibitor?
  5. 5.How often will we monitor my eGFR and urine protein to see if the treatment is working?
  6. 6.If this is polyclonal ITG, have we ruled out all possible underlying infections (like HIV or Hepatitis) or autoimmune conditions?

References

References (15)
  1. 1

    Immunotactoid Glomerulopathy.

    Abramson M, Shaikh A

    Advances in kidney disease and health 2024; (31(4)):326-333 doi:10.1053/j.akdh.2024.03.003.

    PMID: 39084758
  2. 2

    Monoclonal gammopathy of renal significance: Spectrum of diseases and approach to a case.

    Tewari R, Chatterjee T, Mendonca S, et al.

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2021; (32(2)):298-306 doi:10.4103/1319-2442.335440.

    PMID: 35017322
  3. 3

    Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance.

    Sprangers B, Cohen C, Gnemmi V, et al.

    Clinical kidney journal 2026; (19(6)):sfag163 doi:10.1093/ckj/sfag163.

    PMID: 42338690
  4. 4

    Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.

    Javaugue V, Dufour-Nourigat L, Desport E, et al.

    Kidney international 2021; (99(2)):421-430 doi:10.1016/j.kint.2020.06.039.

    PMID: 32739419
  5. 5

    Successful Treatment of Monoclonal Immunotactoid Glomerulopathy Associated with Chronic Lymphocytic Leukemia Using Ibrutinib.

    Saito A, Kameoka Y, Ubukawa K, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(9)):1388-1392 doi:10.2169/internalmedicine.3902-24.

    PMID: 39370258
  6. 6

    A case report of unusually long lag time between immunotactoid glomerulopathy (itg) diagnosis and diffuse large B-cell lymphoma (DLBCL) development.

    Khandelwal A, Trinkaus MA, Ghaffar H, et al.

    BMC nephrology 2016; (17(1)):140 doi:10.1186/s12882-016-0349-9.

    PMID: 27686684
  7. 7

    Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen.

    Quattrocchio G, Barreca A, Vaccarino A, et al.

    Frontiers in medicine 2020; (7()):587345 doi:10.3389/fmed.2020.587345.

    PMID: 33392216
  8. 8

    Treatment with Daratumumab for Immunotactoid Glomerulopathy Associated with Plasma Cell Dyscrasia: A Report of Two Cases.

    Uehara A, Oura M, Ikeda D, et al.

    Internal medicine (Tokyo, Japan) 2026; (65(9)):1268-1272 doi:10.2169/internalmedicine.5165-24.

    PMID: 40930824
  9. 9

    Light Chain-Only Immunotactoid Glomerulopathy: A Case Report.

    Bu L, Javaugue V, Chauvet S, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2023; (81(5)):611-615 doi:10.1053/j.ajkd.2022.08.025.

    PMID: 36328099
  10. 10

    Immunotactoid Glomerulopathy in a Patient With HIV and Anti-hepatitis C Virus (HCV) Positivity: A Unique Clinical Entity.

    Wagle A, Shrestha R, Varma N

    Cureus 2025; (17(8)):e90015 doi:10.7759/cureus.90015.

    PMID: 40951240
  11. 11

    HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents.

    Angeletti A, Cantarelli C, Cravedi P

    Frontiers in medicine 2019; (6()):20 doi:10.3389/fmed.2019.00020.

    PMID: 30800660
  12. 12

    Immunotactoid glomerulopathy in rheumatoid arthritis.

    Dejman A, Velez Torres JM, Tjendra Y, et al.

    Clinical nephrology. Case studies 2025; (13()):77-83 doi:10.5414/CNCS111805.

    PMID: 41409235
  13. 13

    Immunotactoid Glomerulopathy: A Rare Glomerular Disease Case Study.

    Karanfilovski V, Ristovska V, Gjorgjievski N, et al.

    Indian journal of nephrology 2023; (33(2)):140-143 doi:10.4103/ijn.ijn_107_22.

    PMID: 37234440
  14. 14

    The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

    Leung N, Bridoux F, Batuman V, et al.

    Nature reviews. Nephrology 2019; (15(1)):45-59 doi:10.1038/s41581-018-0077-4.

    PMID: 30510265
  15. 15

    Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants.

    Nasr SH, Kudose SS, Said SM, et al.

    Kidney international 2021; (99(2)):410-420 doi:10.1016/j.kint.2020.07.037.

    PMID: 32818517

This page explains treatment options and kidney-protection strategies for immunotactoid glomerulopathy for informational purposes only and does not constitute medical advice. Your nephrologist and hematologist or oncologist should tailor treatment and monitoring to your biopsy, blood tests, and kidney function.